Glial Fibrillary Acidic Protein Alpha Subunit Antibody, Immunofluorescence Titer Assay, Spinal Fluid
Use
This test is useful for reporting an end titer result in spinal fluid specimens to distinguish autoimmune GFAP astrocytopathy from infectious meningoencephalitis and idiopathic inflammatory CNS disorders such as multiple sclerosis, vasculitis, and sarcoidosis. It alerts the clinician that the patient may have an immune-mediated, steroid-responsive disorder and prompts a search for a malignancy.
Special Instructions
Not provided.
Limitations
Negative results do not exclude the diagnosis of autoimmune meningoencephalomyelitis or cancer. Improper specimen collection and handling or inappropriate test selection may cause diagnostic confusion.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
Glial Fibrillary Acidic Protein (GFAP)
Protein
LOINC Codes
- 93421-6 - GFAP alpha IgG Titr CSF IF
- 93421-6 - GFAP alpha IgG Titr CSF IF
Result Turnaround Time
10 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
1.5 mL
Container
Sterile vial
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |